Nordic Life Science

"This is a development that threatens the entire sensitive ecosystem of life science innovation that has emerged," says Jessica Martinsson @SwedenBIO nordiclifescience.org/new-trump-camp…

@AstraZeneca plans to harmonize its share listing structure to deliver “a global listing for global investors in a global company”. nordiclifescience.org/astrazeneca-sw…

"Further, this exemplifies our strategic approach to monetize value through high-impact partnerships," says Birgitte Rønø, CSO and interim CEO of @EvaxionBiotech nordiclifescience.org/evaxion-out-li…

@Genmab believes that petosemtamab will be accretive to EBITDA with at least one-billion-dollar annual sales potential by 2029, with multi-billion-dollar annual revenue potential thereafter. @MerusNV nordiclifescience.org/genmab-to-acqu…

The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. nordiclifescience.org/anocca-raises-…

Under the terms of the agreement, CSPC will receive an upfront payment of USD 110 million. @AstraZeneca nordiclifescience.org/astrazeneca-en…

This initiative by @EU_Commission focused first on the science component promoting a unified European approach to attract and retain talent, thereby strengthening Europe’s competitiveness. nordiclifescience.org/european-commi…

Bara hälften av nya läkemedel i EU når svenska patienter. Av 173 läkemedel som godkändes av europeiska läkemedelsmyndigheten EMA mellan 2020 och 2023 var bara 86 tillgängliga i Sverige i början av 2024. Det placerar Sverige på 17:e plats i Europa i årets WAIT-rapport – och påverkar patienters tillgång till nya behandlingar. Kartläggningen är en signal om att det finns stora utmaningar i det svenska läkemedelssystemet när det gäller beslutsprocesserna för att införa nya läkemedel.

This collaboration represents a powerful alignment of capabilities designed to address the growing complexity of global regulatory requirements, the companies state. @RecipharmAB nordiclifescience.org/recipharm-ente…

The first study in the US aims to verify the pharmacokinetic profile of a new formulation of AQ280 specifically developed for the treatment of patients with EoE (eosinophilic esophagitis). nordiclifescience.org/aqilion-receiv…

"We believe investors in Sweden, and more broadly in the Nordics and continental Europe, will find Alvotech highly attractive, with a strong and differentiated value proposition," says Róbert Wessman @alvotechpr nordiclifescience.org/alvotech-publi…

For the first time @novonordiskfond is inviting researchers from outside Denmark, in the European Schengen area, Cyprus, Ireland and the UK, to lead collaborations applying for grants to study four major themes. nordiclifescience.org/novo-nordisk-f…

#AAXBiotechAB has announced a new collaboration focused on developing antibody-based therapies for acute and critical care of cardiovascular disease. nordiclifescience.org/aax-biotech-en…

The investments not only enhance @HealthCapVC ability to support transformative healthcare companies but also reinforce the Nordic region’s position as a global leader in life science innovation and entrepreneurship," says Mårten Steen, Managing Partner nordiclifescience.org/novo-holdings-…

"We are pleased with the CHMP’s positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly," says Fredrik Tiberg, Camurus nordiclifescience.org/chmp-recommend…

"We are interested in identifying new targets for interventions that could then be used to develop new drugs and vaccines or help us understand why some mosquito species transmit malaria while others do not." @umeauniversitet #WorldMalariaDay2025 nordiclifescience.org/world-malaria-…

"To be able to control costs and serve patients, the world will need biosimilars," says Róbert Wessman, Icelandic businessman and entrepreneur @alvotechpr nordiclifescience.org/global-health-…

The Board @Biotage has decided to recommend that Biotage shareholders accept the offer. @KKR_Co nordiclifescience.org/kkr-makes-sek-…

"The EU has a choice to make. Either we act and secure Europe’s position as a leading region for research and innovation, or we watch as others take the lead," says Sofia Wallström, CEO @LIFse nordiclifescience.org/joint-swedish-…

This is the first therapy targeting an underlying cause of Alzheimer’s disease (AD) to be granted an MA in the EU. @bioarcticab nordiclifescience.org/eu-approves-le…